A Two Year Phase IIIb Randomised, Multicenter, Double-Blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole Add-on Therapy to L-Dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects.

Trial Profile

A Two Year Phase IIIb Randomised, Multicenter, Double-Blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole Add-on Therapy to L-Dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs Levodopa/carbidopa; Ropinirole
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 May 2009 Actual end date changed from Dec 2005 to Dec 2003 as reported by ClinicalTrials.gov.
    • 25 Aug 2007 Results hace been reported at EFNS 2007 (1084799)
    • 25 Aug 2007 Status changed from in progress to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top